Introduction The primary objective of our study was to describe the variation of anti-citrullinated protein antibodies (ACPA) antibody levels in patients with rheumatoid arthritis (RA) under disease-modifying therapy. This evidence concerns the gene PRTN3 and rheumatoid arthritis.